We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
1
Sep 2026
New research from the Marshall University Joan C. Edwards School of Medicine provides insight into how binge alcohol exposure during adolescence may cause lasting changes in brain function that persist into adulthood, potentially identifying a new target for future treatment approaches.
31
Aug 2026
Regular aerobic exercise – the kind that gets your heart pumping – can improve important thinking skills called executive functions, and the benefits appear especially strong for women after menopause, according to Rutgers researchers.
31
Aug 2026
A cross-sectional study of children aged 4 to 9 found that greater caregiver-reported daily screen time was associated with lower contrast sensitivity and differences in how age related to visual-search performance. The associations varied by visual feature and task demands, suggesting that screen exposure may relate differently to lower-level visual processing and selective attention across middle childhood.
31
Aug 2026
A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.